Multiple cerebral lesions in a patient with refractory celiac disease: A case report

Lena Horvath, Georg Oberhuber, Andreas Chott, Maria Effenberger, Herbert Tilg, Eberhard Gunsilius, Dominik Wolf, Sarah Iglseder

ORCID number: Lena Horvath 0000-0002-1509-4324; Georg Oberhuber 0000-0002-9701-821X; Andreas Chott 0000-0002-0179-838X; Maria Effenberger 0000-0002-0499-9953; Herbert Tilg 0000-0002-4235-2579; Eberhard Gunsilius 0000-0003-1327-2921; Dominik Wolf 0000-0002-4761-075X; Sarah Iglseder 0000-0002-0912-7257.

Author contributions: Horvath L and Iglseder S wrote and corrected the manuscript; Oberhuber G, Gunsilius E, Wolf D, Effenberger M, Tilg H and Chott A reviewed and corrected the manuscript; Oberhuber G and Iglseder S provided the figures; Iglseder S was the patient’s neurologist; Effenberger M and Tilg H were the patient’s gastroenterologists; Horvath L, Gunsilius E and Wolf D were the patient’s haematologists; Oberhuber G and Chott A were the pathologists involved; all authors issued final approval for the version to be submitted.

Informed consent statement: Any and all details that might disclose the identity of the patient described in this report are anonymized. The patient has deceased at the time point of enrollment, writing and submission of this case report and therefore not informed written.

Abstract

BACKGROUND
Enteropathy-associated T cell lymphoma (EATL) is an aggressive intestinal T cell lymphoma derived from intraepithelial lymphocytes, which occurs in individuals with celiac disease (CD). Cerebral involvement is an extremely rare condition and as described so far, lymphoma lesions may present as parenchymal preponderantly supratentorial or leptomeningeal involvement. We describe a case of EATL with multifocal supra- and infratentorial brain involvement in a patient with refractory celiac disease (RCD).

CASE SUMMARY
A 58-years old man with known CD developed ulcerative jejunitis and was diagnosed with RCD type II. Six months later he presented with subacute cerebellar symptoms (gait ataxia, double vision, dizziness). Cranial magnetic resonance imaging (MRI) revealed multifocal T2 hyperintense supra- and infratentorial lesions. Laboratory studies of blood and cerebrospinal fluid were inconspicuous for infectious, inflammatory or autoimmune diseases. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) scan showed a suspect hypermetabolic lesion in the left upper abdomen and consequent surgical jejunal resection revealed the diagnosis of...
A 58-years old man with the known history CD consulted his gastroenterologist due to upper stomachache, postprandial bloating and involuntary weight loss (15 kg within one month).

**Chief complaints**
A 58-years old man with the known history CD consulted his gastroenterologist due to upper stomachache, postprandial bloating and involuntary weight loss (15 kg within one month).

**INTRODUCTION**
Enteropathy-associated T cell lymphoma (EATL) is a rare and aggressive type of peripheral T cell lymphoma (PTCL), accounting for approximately 5% of PTCL. It is a primary intestinal lymphoma, typically affecting the jejunum and ileum, and is often associated with celiac disease (CD). Extraintestinal involvement is a rare complication with poor prognosis. Concerning cerebral involvement, predominantly supratentorial parenchymal lesions or leptomeningeal involvement have been described in few case reports, either as primary cerebral lymphoma or secondary to intestinal EATL, whereas infratentorial lesions are extremely rare and were only reported once. We herein present an extraordinary case of EATL with simultaneous multifocal supra- and infratentorial brain involvement in a patient with refractory celiac disease (RCD).

**CASE PRESENTATION**

**Chief complaints**
A 58-years old man with the known history CD consulted his gastroenterologist due to upper stomachache, postprandial bloating and involuntary weight loss (15 kg within one month).
History of present illness
Nine years earlier the previously healthy man was diagnosed with CD (histologically Marsh-Oberhuber type 1, genotype HLA-DQB1*02, elevated immunoglobulin Atissue transglutaminase (tTG-IgA) antibodies) after a period of severe diarrhea. The patient swiftly recovered upon starting a strict gluten-free diet and went into histological and clinical remission.

History of past illness
Apart from CD, the patient had no relevant previous illnesses.

Personal and family history
Family history was inconspicuous.

Physical examination
At the actual consultation the patient presented in normal nutritional, but slightly reduced general condition. Physical examination revealed diffuse tenderness of the abdomen, but otherwise no abnormal findings. Clinical neurological examination was unsuspicious.

Laboratory examinations
Laboratory studies, including total blood count, kidney, liver as well as inflammatory parameters did not reveal any abnormalities. Fecal analysis showed a calprotectin above 1000 µg/g (normal count < 50 µg/g). Serologic tTG-IgA antibodies were normal and suggested dietary well controlled CD.

Imaging examinations
As initial gastroscopic evaluation was inconspicuous, contrast MRI of the abdomen was performed exposing prominent mesenterial lymphadenopathy in the left upper abdominal quadrant. Capsule endoscopy revealed ulcerative lesions in the proximal jejunum and ileum, which were consequently biopsied via push-endoscopy.

Further diagnostics and clinical course
Histological examination of the jejunal biopsies revealed ulcerative jejunitis type II (Figure 1) with an increased population of immunophenotypically abnormal intraepithelial lymphocytes (IEL) (Figure 2). Diagnosis of RCD type II was made and an immunosuppressive therapy with methylprednisolone and azathioprine initiated. The patient’s condition slightly improved within weeks.

Six months later, the patient suffered from subacute gait ataxia, undirected dizziness, double vision and cognitive impairment with aggravation over the course of four days. A cranial MRI revealed multifocal T2 hyperintense partially ring-enhancing lesions cortical, subcortical, periventricular, in the basal ganglia, mesencephalon and cerebellum. The cell count in the cerebrospinal fluid (CSF) was normal. No malignant tumor cells, pathogens or oligoclonal bands were detected. Neurotropic pathogens were ruled out via polymerase chain reaction (PCR). Electroencephalography (EEG) showed moderate diffuse cerebral dysfunction but no epileptiform abnormalities. Onconeural antibodies and antibodies to neuronal surface antigens in serum and CSF remained negative.

Due to rapid worsening of the patient’s neurological condition, particularly progression of the cerebellar syndrome, an empiric therapy with intravenous high-dose methylprednisolone (1 g daily for five days) was initiated and clinical improvement followed promptly. Yet, repeated cranial MRIs showed the intracranial lesions stable in size and location.

For further evaluation, an 18FDG-PET/CT scan was performed revealing a hypermetabolic lesion in the left upper abdomen. Recurrent endoscopic biopsies of the respective jejunal ulcerations indicated the known diagnosis of RCD type II. Due to high clinical suspicion of lymphoma, the patient consequently underwent surgical resection of the affected jejunal part.

During the period of diagnostic testing, the patient’s neurological condition worsened with permanent dizziness and progressive right-sided hemiparesis. Recurrent cranial MRIs revealed progressive multifocal supra- and infratentorial lesions with diffusion restriction as well as inhomogeneous and circular contrast enhancement, morphologically compatible with central nervous system (CNS) lymphoma (Figure 3). Once more, CSF analysis did not reveal any remarkable findings, especially no malignant cells.
Figure 1 Biopsies from an area with ulcerative jejunitis. On the right there is an erosion without lymphomatous involvement. Adjacent mucosa shows villous flattening. Magnification 200 ×.

Figure 2 Histological presentation of refractory celiac disease type 2. A: Normal villous architecture with an increase in intraepithelial lymphocytes. Hematoxylin and eosin; B: Intraepithelial CD3 positive lymphocytes (brown color) are abundant; C: Intraepithelial lymphocytes contain TIA-1 positive granules (brown color, arrow); D: Intraepithelial lymphocytes are CD8 negative (arrow), positive reaction in brown coloration. Magnification 200 × (A, B and D) and 400 × (C).

FINAL DIAGNOSIS

Histological workup of the jejunal specimen confirmed the diagnosis of EATL with infiltration of the subserosa and covered perforation (Figure 4A and 8). Resection lines were free of tumor. Consequently, the cerebral lesions were interpreted as CNS involvement of the EATL.

TREATMENT

A chemotherapy with intravenous methotrexate (4 mg/m², total dose 8160 mg) was
administered as single dose.

OUTCOME AND FOLLOW-UP

Unfortunately, the patient showed only transient and little clinical improvement in response to methotrexate. Given this discrepancy and the hope to re-define diagnosis, a brain biopsy was performed. Histopathological examination by Prof. Hainfellner J (Medical University Vienna, Division of Neuropathology) could lastly confirm the suspicion of cerebral involvement of primary intestinal EATL (Figure 4C and D).

Due to poor prognosis and lack of therapeutic options, the patient was transferred to a hospice facility. He passed away three weeks after the definitive diagnosis had been made.

DISCUSSION

EATL is a rare and aggressive primary intestinal lymphoma, accounting for approximately 5% of PTCL cases, with an incidence of 0.05-0.14/100000 in Europe[1]. It may evolve de novo or progress from RCD (particularly RCD type II) via a multi-step process. RCD is defined as lack of clinical and histological response to at least twelve months of rigid gluten free diet (i.e., normalization of antibody titers) and after exclusion of other possible causes of villous atrophy. RCD may present in form of chronic ulcerative jejunitis[1]. While patients with de novo EATL show a 5-year overall survival (OS) of 59%, those cases evolving from RCD type II show a poor prognosis with 5-year OS of 0%-8%[1]. In these patients extraintestinal manifestations are seen more frequently.

Clinical presentation

EATL most frequently occurs in the 5th to 6th decade and is usually diagnosed in advanced disease stages, as it was seen in our case. Typical symptoms include
abdominal pain, vomiting/nausea, B symptoms as well as signs of intra-abdominal sepsis or intestinal perforation. Time span between diagnosis of CD and EATL varies between a few months to several decades\(^2\). In our patient, it was eight years.

The small intestine is the most commonly affected site (jejunum, ileum, duodenum in descending order) with frequent involvement of mesenteric, para-aortic or iliac lymph nodes\(^2\), as also observed in our case. Bone marrow involvement is uncommon\(^9\) and was not seen in our patient. Furthermore, EATL may be observed in the stomach\(^3\), colon\(^11\), liver, lung and skin\(^12\). Cerebral manifestation is extremely rare\(^2\) and up to now, six case reports, either as primary cerebral lymphoma or secondary to intestinal EATL, have been published\(^3-8\). When EATL involves the CNS, it may present as lymphomatous dissemination in the form of parenchymal lesions predominantly supratentorial or as leptomeningeal involvement\(^3,6,14\). The MRI scans of our patient showed not only multifocal supratentorial lesions, but also brainstem and cerebellar involvement, which has been described only once so far\(^5\).

In our patient, cerebellar ataxia was the most apparent neurological symptom. Differential diagnosis of acute or subacute cerebellar ataxia associated with RCD include gluten ataxia and paraneoplastic cerebellar syndrome. Other neurological symptoms from supratentorial metastasis involve headache, changes in mental status, seizures and paresis\(^3-8\). The time period from intestinal manifestation to CNS involvement varies, with development of neurological symptoms within month or years after primary diagnosis\(^4\).

**Diagnostic confirmation**

EATL is usually diagnosed by histopathological examination of small bowel biopsies or resection specimens and is based upon characteristic histological and immunophenotypic findings as well as T cell clonality analysis. In our patient, EATL only scarcely affected the intestinal mucosa but showed predominant destruction of muscularis and subserosa, therefore endoscopic biopsies were repeatedly inconclusive. In the jejunal resection specimen diagnosis could lastly be made. In case of brain involvement, radiological diagnosis is best accomplished by contrast-enhanced T1 and T2 weighted MRI, demonstrating either a diffuse high intensity signal along the CSF space in case of leptomeningeal seeding, or a localized irregular, ill-defined enhancing lesion exemplifying parenchymatous penetration\(^3-5\). As demonstrated in our patient, biopsies or resection of extraintestinal manifestations including cerebral lesions can be
considered to confirm diagnosis in cases of inconclusive histological results or poor treatment response.

**Morphology**

Histologically, the jejunal resection specimen showed an infiltration of medium- to large-sized lymphoid cells with anaplastic features (Figure 4A and B). Immunophenotypically, the neoplastic cells were CD30+, CD103+, CD8+, CD7+, granzyme B+ (Figure 4B) as well as TCRδ+, but negative for βF1, CD4, CD2, CD5, and CD56. The cerebral biopsy showed a loosely scattered infiltration of very similar large anaplastic CD3+ tumor cells (Figure 4C and D).

**Treatment**

In EATL, the primary treatment involves surgical local debulking followed by systemic chemotherapy, preferably two to five weeks after surgery[15-17], as also performed in our patient. Up to now, there is no standard chemotherapy protocol for EATL. In PTCL, anthracycline-based chemotherapy is widely used such as cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like chemotherapy[18,19]. The aggressive combination of ifosfamide, epirubicin, and etoposide (IVE) with intermediate-dose methotrexate (MTX) followed by autologous stem cell transplantation (ASCT) has shown potent anti-tumor effect and improved response rate in patients with EATL[20]. Unfortunately, a great number of patients are unable to complete chemotherapy due to poor performance status and severe malnutrition[17,20]. As for targeted therapy approaches, the CD30-directed antibody drug conjugate brentuximab-vedotin (BV) is of particular interest, having shown to improve outcomes in patients with CD30+ PTCL in combination with chemotherapy. Currently, data on the effect of BV in patients with EATL is limited, however few encouraging results of BV either in combination with intensive chemotherapy/ASCT[21] or as monotherapy[22] have been reported. Further studies are ongoing (e.g., NCT03217643). Other targeted drugs, such as histone deacetylase (HDAC) inhibitors or immune-checkpoint inhibitors are under clinical investigation in PTCL including EATL, however most studies exclude cerebral involvement.

Neurosurgical indication for resection of symptomatic cerebral lesions is similar to that of other types of intracranial metastasis and may be followed by focal or whole brain radiotherapy. In case of leptomeningeal involvement, the best treatment options are chemotherapy, followed by craniospinal irradiation[3-6]. In our patient, after surgical resection of the affected jejunal part, a systemic chemotherapy with methotrexate was started. Unfortunately, the patient’s status deteriorated quickly after a short transient clinical improvement after the chemotherapy, therefore treatment was switched to best supportive care. Considering our case and previously reported findings, the prognosis and outcome of EATL with CNS involvement is poor and is not significantly improved by aggressive surgical and systemic treatments.

In summary, EATL may present with primary or secondary extraintestinal manifestations, with brain involvement being an extremely rare complication with poor prognosis despite aggressive surgical and medical treatment. To our knowledge, this is the first reported EATL case with simultaneous multifocal supra- and infratentorial brain involvement. As demonstrated in our patient, a biopsy of extraintestinal manifestations including biopsy or resection of cerebral lesions could be considered to confirm diagnosis in case of inconclusive histological results or poor treatment response.

**CONCLUSION**

EATL with cerebral involvement is a rare but severe complication and must be considered as a diagnostic possibility when a patient with known RCD presents with neurological deterioration. A multidisciplinary approach to the disease is required for both an early diagnosis and prompt treatment, increasing the likelihood of a positive outcome.

**ACKNOWLEDGEMENTS**

We thank Professor Hainfellner J (Medical University Vienna, Division of Neuropathology) for providing histopathological figures of the cerebral biopsy.
1. Chander U, Leeman-Neill RJ, Blagat G. Pathogenesis of Enteropathy-Associated T Cell Lymphoma. *Curr Hematol Malig Rep* 2018; 13: 308-317 [PMID: 29943210 DOI: 10.1007/s11899-018-0459-5]

2. Delabie J, Holte H, Vose JM, Ulrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. *Blood* 2011; 118: 148-155 [PMID: 21566094 DOI: 10.1182/blood-2011-02-335216]

3. Gobbi C, Bues M, Probst A, Ruegg S, Schraml P, Herrmann R, Steck AJ, Dirnhofer S. Enteropathy-associated T-cell lymphoma with initial manifestation in the CNS. *Neurology* 2003; 60: 1718-1719 [PMID: 12771280 DOI: 10.1212/01.wnl.000066052.84194.6e]

4. Tutt AN, Brada M, Sampson SA. Enteropathy-associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T-cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder. *Gut* 1997; 40: 801-803 [PMID: 9245937 DOI: 10.1136/gut.40.6.801]

5. Shams PN, Waldman A, Dogan A, MacKenzie JM, Plant GT. Ataxia in the setting of complicated enteropathy: double jeopardy. *J Neurol Neurosurg Psychiatry* 2002; 72: 527-529 [PMID: 11909917 DOI: 10.1136/jnnp.72.4.527]

6. Berman EL, Zauber NP, Rickert RR, Diss TC, Isaacson PG. Enteropathy-associated T cell lymphoma with brain involvement. *J Clin Gastroenterol* 1998; 26: 337-341 [PMID: 9649024 DOI: 10.1007/90004836-19980600-00026]

7. Defillo A, Zelenksy A, Simmons BH, Nussbaum ES. Supratentorial metastatic enteropathy-associated T-cell lymphoma: A case report and literature review. *Surg Neurol Int* 2012; 3: 144 [PMID: 22323525 DOI: 10.4103/2152-7806.103887]

8. Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA. Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. *Acta Gastroenterol Belg* 2020; 83: 77-80 [PMID: 32323376]

9. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127: 2375-2390 [PMID: 26980727 DOI: 10.1182/blood-2016-01-643569]

10. Hong YS, Woo YS, Park G, Lee K, Kang SH, Lee HW, Kim ER, Hong SN, Chang DK, Kim YH, Rhee PL, Kim JJ. Endoscopic Findings of Enteropathy-Associated-Cell Lymphoma Type II: A Case Series. *Gut Liver* 2016; 10: 147-151 [PMID: 26260757 DOI: 10.5009/gnl14457]

11. Kim JB, Kim SH, Cho YK, Ahn SB, Jo YJ, Park YS, Lee JH, Kim DH, Lee H, Jung YY. A case of colon perforation due to enteropathy-associated T-cell lymphoma. *World J Gastroenterol* 2013; 19: 1841-1844 [PMID: 23555174 DOI: 10.3748/wjg.v19.i11.1841]

12. Malanunt G, Chandesris O, Verkarre V, Meresse B, Callens C, Macintyre E, Bouhnik Y, Gornet JM, Altet M, Jian R, Berger A, Chatellier G, Brousse N, Hermine O, Cerf-Bensussan N, Cellier C. Enteropathy-associated T cell lymphoma in celiac disease: a large retrospective study. *Dig Liver Dis* 2013; 45: 377-384 [PMID: 23313469 DOI: 10.1016/j.dld.2012.12.001]

13. Meijer JW, Mulder CJ, Goeres MG, Boot H, Schweizer JJ. Coeliac disease and (extra)intestinal T-cell lymphomas: definition, diagnosis and treatment. *Scand J Gastroenterol Suppl* 2004; : 78-84 [PMID: 15696854 DOI: 10.1080/008559204100146460]

14. Ang LC, Zachodnie DW, Ebers GC, Kaufmann JC, Vinters HV. Severe cerebellar degeneration in a patient with T-cell lymphoma. *Acta Neuropathol* 1986; 69: 171-175 [PMID: 3485877 DOI: 10.1007/BF00687056]

15. Daum S, Ulrich R, Heise W, Dederke B, Foss HD, Stein H, Thiels J, Zeitz M, Riecken EO. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. *J Clin Oncol* 2003; 21: 2740-2746 [PMID: 12860953 DOI: 10.1200/JCO.2003.06.026]

16. Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. *J Clin Gastroenterol* 1995; 21: 123-129 [PMID: 8583077 DOI: 10.1097/00004836-199509000-00012]

17. Gale J, Simmons PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. *J Clin Oncol* 2000; 18: 795-803 [PMID: 10675521 DOI: 10.1200/JCO.2000.18.4.795]

18. Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Bowerett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M; ALLG. A phase III randomized trial of high-dose CEOP + filgrastim vs standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. *Am J Hematol* 2014; 89: 536-541 [PMID: 24481640 DOI: 10.1002/ajh.23684]

19. Cai MC, Cheng S, Wang X, Hu JD, Song YP, Huang YH, Yan ZX, Jiang YJ, Fang XS, Zheng XY, Dong LH, Ji MM, Wang L, Xu PP, Zhao WL. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with T-cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. *Genome Med* 2020; 12: 41 [PMID: 32349779 DOI: 10.1186/s13073-020-00739-0]
20 **Sieniawski M**, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, Jack F, Lyons S, Mounter P, Revell P, Proctor SJ, Lennard AL. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. *Blood* 2010; **115**: 3664-3670 [PMID: 2097555] DOI: 10.1182/blood-2009-07-231324]

21 **Sibon D**, Malanut G, Verkarre V, Derrieux C, Radford I, Meresse B, Macintyre E, Cellier C, Cerf-Bensussan N, Brousse N, Hermine O. Enteropathy-Associated T-Cell Lymphoma Type I, But Not Refractory Celiac Disease, Strongly Expresses CD30 and Might Benefit From Brentuximab Vedotin. *Blood* 2013; **122**: 4252-4252 [DOI: 10.1182/blood.V122.21.4252.4252]

22 **Khalaf WF**, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. *J Natl Compr Canc Netw* 2013; **11**: 137-40; quiz 140 [PMID: 23411380 DOI: 10.6004/jnccn.2013.0021]
